Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/3877

TDMS Study 05069-06 Pathology Tables

                                     INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
                                                1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE


NTP Experiment-Test: 05069-06                                                                                     Report: PEIRPT03
Study Type: INIT/PROMOT                                                                                           Date: 10/19/93
Route: DERMAL,SOLUTION                                                                                            Time: 13:41:28




       Facility:  TSI Mason Research

       Chemical CAS #:  147-47-7

       Lock Date:  09/17/93

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include 011    ACETONE/ACETONE
                               Include 004    ACET/TMQ5 MG/KG
                               Include 005    ACET/TMQ10 MG/KG
                               Include 006    ACET/TMQ25 MG/KG





























a  Number of animals examined microscopically at site and number of animals with lesion

                                                             Page   1
NTP Experiment-Test: 05069-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: INIT/PROMOT                            1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE                           Date: 10/19/93    
Route: DERMAL,SOLUTION                                                                                            Time: 13:41:28    
____________________________________________________________________________________________________________________________________

         SENCAR MICE FEMALE                   ACETONE/        ACET/TMQ     ACET/TMQ     ACET/TMQ                                    
                                               ACETONE         5 MG/KG      10 MG/KG     25 MG/KG                                    
____________________________________________________________________________________________________________________________________

DISPOSITION SUMMARY                                                                                                                 

  Animals Initially In Study                      30              30           30           30                                       
  Early Deaths                                                                                                                      
    Natural Death                                                  1            1            2                                       
    Moribund Sacrifice                             2                                         1                                       
  Survivors                                                                                                                         
    Terminal Sacrifice                            27              29           29           27                                       
    Natural Death                                  1                                                                                 

  Animals Examined Microscopically                30              30           30           30                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                          (30)            (30)         (30)         (30)                                     
      Angiectasis                                                              1 (3%)                                               
      Congestion                                  1 (3%)          2 (7%)       1 (3%)                                               
      Eosinophilic Focus                          1 (3%)                                                                            
      Hematopoietic Cell Proliferation            7 (23%)         4 (13%)      6 (20%)      6 (20%)                                 
      Inflammation, Chronic                                       2 (7%)       2 (7%)       1 (3%)                                  
      Necrosis                                                    2 (7%)       1 (3%)                                               
      Pigmentation                                2 (7%)                                                                            
      Periportal, Fibrosis                        1 (3%)                                                                            
   Salivary Glands                                               (1)                                                                
      Interlobular, Edema                                         1 (100%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    

a  Number of animals examined microscopically at site and number of animals with lesion                                             








                                                             Page    2                                                              
NTP Experiment-Test: 05069-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: INIT/PROMOT                            1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE                           Date: 10/19/93    
Route: DERMAL,SOLUTION                                                                                            Time: 13:41:28    
____________________________________________________________________________________________________________________________________

         SENCAR MICE FEMALE                   ACETONE/         ACET/TMQ     ACET/TMQ     ACET/TMQ                                   
                                               ACETONE          5 MG/KG      10 MG/KG     25 MG/KG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                         (1)              (1)                       (1)                                     
      Cyst                                                         1 (100%)                  1 (100%)                               
      Hematocyst                                  1 (100%)                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Spleen                                        (1)                                        (1)                                     
      Hematopoietic Cell Proliferation            1 (100%)                                   1 (100%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                          (30)             (30)         (30)         (30)                                    
      Back, Acanthosis                                             1 (3%)       3 (10%)      1 (3%)                                 
      Back, Inflammation, Chronic                                               3 (10%)      1 (3%)                                 
      Back, Inflammation, Chronic Active                                        1 (3%)                                              
      Inguinal, Inflammation, Chronic             2 (7%)           1 (3%)       3 (10%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (1)                       (1)          (1)                                    
      Cyst                                             1 (100%)                  1 (100%)                                           
      Inflammation, Chronic Active                                                            1 (100%)                              
      Nephropathy                                      1 (100%)                                                                     

a  Number of animals examined microscopically at site and number of animals with lesion                                             



                                                             Page    3                                                              
NTP Experiment-Test: 05069-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: INIT/PROMOT                            1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLINE                           Date: 10/19/93    
Route: DERMAL,SOLUTION                                                                                            Time: 13:41:28    
____________________________________________________________________________________________________________________________________

         SENCAR MICE FEMALE              ACETONE/     ACET/TMQ     ACET/TMQ     ACET/TMQ                                   
                                          ACETONE      5 MG/KG      10 MG/KG     25 MG/KG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
URINARY SYSTEM - CONT                                                                                                               
      Cortex, Mineralization                                        1 (100%)                                                         
      Papilla, Necrosis                   1 (100%)                                                                                   
      Renal Tubule, Degeneration, Hyaline                                        1 (100%)                                           
                                                                                                                                    

a  Number of animals examined microscopically at site and number of animals with lesion                                             














































                                                             Page    4                                                              
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------